Understanding calcium signaling and autophagy issues in Alzheimer's disease neurons
Calcium signaling and autophagy defects in Alzheimer's disease neurons
This study is looking at how problems with cell cleaning and calcium levels in the brain might play a role in Alzheimer's disease, using special mice to test new ways to help brain cells stay healthy, which could lead to better treatments for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11022985 on NIH RePORTER |
What this research studies
This research investigates how defects in autophagy and calcium signaling contribute to Alzheimer's disease. By using a transgenic mouse model of Alzheimer's, the team will explore the effects of specific inhibitors and modulators on neuronal health. The goal is to identify potential therapeutic targets that could improve neuronal function and protect against the progression of Alzheimer's. Patients may benefit from insights gained that could lead to new treatments for the disease.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are individuals diagnosed with Alzheimer's disease or those at risk due to genetic factors.
Not a fit: Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve neuronal health and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting calcium signaling and autophagy in Alzheimer's models, suggesting potential for success in this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Yamamoto, Ai — Columbia University Health Sciences
- Study coordinator: Yamamoto, Ai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.